not yet established.Contraindications:Not to be used with an MAOI or within paroxetine en zwangerschap days of starting paroxetine en zwangerschap paroxetine en zwangerschap MAOI therapy. Concomitant administration of paroxetine en zwangerschap Contraindicated in paroxetine en zwangerschap < 18 years of age due to possible increased risk of suicide-related events in this patient populations.Precautions:Not.

neuroleptic malignant paroxetine en zwangerschap paroxetine en zwangerschap paroxetine en zwangerschap hepatic impairment, activation paroxetine en zwangerschap mania/hypomania, suicidal tendency, MI or unstable heart disease. paroxetine en zwangerschap of combined Paxil and electroconvulsive therapy has not been studied. Hyponatremia (reversible), abnormal bleeding. If a decision is made to stop Paxil paroxetine en zwangerschap the drug should be gradually withdrawn, as abrupt discontinuation may cause withdrawal symptoms.Side paroxetine en zwangerschap somnolence, paroxetine en zwangerschap tremor, insomnia, asthenia, dry mouth, dizziness, male sexual dysfunction, constipation, diarrhea, decreased appetite.Interactions:See Contraindications. paroxetine en zwangerschap Phenobarbital, theophylline, 5HT1 agonists paroxetine en zwangerschap sumatriptan), phenytoin, paroxetine en zwangerschap anticoagulants (increased bleeding), procyclidine, cimetidine, St. John's Wort, paroxetine en zwangerschap highly bound to plasma protein, drugs affecting liver enzymes. Avoid paroxetine en zwangerschap use of paroxetine and tryptophan.Supplied:12.5 mg and 25 mg controlled-release tablets.Summary paroxetine en zwangerschap IRPAXIL IR GlaxoSmithKlineParoxetine HCIUse:SSRI. Depression.

P450 isozyme (IID6) which is paroxetine en zwangerschap paroxetine en zwangerschap the metabolism of debrisoquine and sparteine. Although the clinical.